Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen

Cell Cycle

Volumn 7, Issue 21, 2008, Pages 3417-3427

  Staples, Oliver D ^a   Hollick, Jonathan J ^b   Campbell, Johanna ^a   Higgins, Maureen ^a   McCarthy, Anna R ^a,b   Appleyard, Virginia ^a   Murray, Karen E ^a   Baker, Lee ^a   Thompson, Alastair ^a   Ronseaux, Sebastien ^a   Slawin, Alexandra M Z ^b   Lane, David P ^a   Westwood, Nicholas J ^b   Lain, Sonia ^a,c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

p53; Small molecule screen; Tubulin polymerization

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; CYCLODEXTRIN; ETHYL 4 (2' HYDROXYBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (2' METHOXYBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (2',5' DIFLUOROBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (2',5' DIFLUOROBENZYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (3' CHLOROBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (3',4' DICHLOROBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (4' CHLOROBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (4' METHOXYBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (4' METHYLBENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 (5' FLUORO 2' MORPHOLIN 4 YL BENZOYL) 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; ETHYL 4 BENZOYL 3,5 DIMETHYL 1H PYRROLE 2 CARBOXYLATE; GEMCITABINE; JJ 78 1; JJ 78 10; JJ 78 11; JJ 78 12; JJ 78 13; JJ 78 14; JJ 78 15; JJ 78 16; JJ 78 17; JJ 78 18; JJ 78 7; JJ 78 8; JJ 78 9; NOCODAZOLE; PACLITAXEL; PROTEIN P53; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ASSAY; CELL CYCLE ARREST; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

EID: 55849126630     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.21.6982     Document Type: Article

References (27)

1. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321-8.
2. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
3. Peterson JR, Mitchison TJ. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. Chem Biol 2002; 9:1275-85.
4. Schreiber SL. The small-molecule approach to biology. Chemical and Engineering News 2003; 81:51-61.
5. Zheng XS, Chan TF, Zhou HH. Genetic and genomic approaches to identify and study the targets of bioactive small molecules. Chem Biol 2004; 11:609-18.
6. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63.
7. Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauquet P, Elhajouji A, Lavia P, Mousset S, Kirsch-Volders M, Cundari E. p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res 1999; 250:339-50.
8. Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, Tseng HY, Lo YK, Chang YL, Chang CM, Hsieh HP. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 2002; 45:2556-62.
9. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209:13-20.
10. Gurley LR, D'Anna JA, Barham SS, Deaven LL, Tobey RA. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 1978; 84:1-15.
11. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, Grushcow JM, Brame CJ, Caldwell JA, Hunt DF, Lin R, Smith MM, Allis CD. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000; 102:279-91.
12. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7.
13. Finzer P, Aguilar-Lemarroy A, Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett 2002; 188:15-24.
14. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Lain S. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 1999; 18:7378-86.
15. Haggarty SJ, Mayer TU, Miyamoto DT, Fathi R, King RW, Mitchison TJ, Schreiber SL. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem Biol 2000; 7:275-86.
16. Yamakawi I, Matsushita Y, Asaka N, Ohmori K, Nomura N, Ogawa K. Synthesis and aldose reductase inhibitory activity of acetic acid derivatives of pyrrolo[1,2-c]imidazole. Eur J Med Chem 1993; 28:481-90.
17. Mizen L, Burton G. The use of esters as prodrugs for oral delivery of β-lactam antibiotics. Pharmaceutical Biotechnology 1998; 11:345-65.
18. Tripathi A, Fornabaio M, Kellogg GE, Gupton JT, Gewirtz DA, Yeudall WA, Vega NE, Mooberry SL. Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity. Bioorganic and Medicinal Chemistry 2008; 16:2235-42.
19. Tani M, Ariyasu T, Nishiyama C, Hagiwara H, Watanabe T, Yokoyama Y, Murakami Y. β-Acylation of ethyl pyrrole-2-carboxylate by Friedel-Crafts acylation; scope and limitations (synthetic studies on indoles and related compounds. XXXVIII). Chemical and Pharmaceutical Bulletin 1996; 44:48-54.
20. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002; 59:1317-26.
21. Blagosklonny MV. Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 2006; 5:971-5.
22. 1 DNA content mediated by prolonged mitosis. Oncogene 2008; 27:4402-10.
23. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006; 54:72-84.
24. Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 1998; 17:1045-52.
25. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, Millis RR, Lane DP, Barnes DM. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993; 29:881-6.
26. 2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology 1991; 19:21-7.
27. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101:183-9.